ClinicalTrials.gg
CompletedNCT00826098Updated Sep 1, 2022

Platelet Rich Plasma (PRP) in Total Knee Replacement

A Phase 4 interventional study of Platelet Rich Plasma in Osteoarthritis and Inflammatory Arthritis, sponsored by Exactech. Completed at 2 sites in United States. Per ClinicalTrials.gov, last updated 2022-09-01.

Sponsored by Exactech · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing platelet rich plasma in Osteoarthritis — 6 open to participants now, 6 under way, 1 of them phase 3. platelet rich plasma · Osteoarthritis.

Enrollment
14th of 28
70 · median 70
Started
2008
the only one that year
Phase 4
7 of 28
2 open now
Registered
1st of 28
by date
Lead sponsor
1 of 28
Exactech

Among the 28 studies testing platelet rich plasma in Osteoarthritis, this one is the 14th largest by enrollment, is the only one that started in 2008, is one of 7 in phase 4, and was the 1st registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

6 of the 28 studies testing platelet rich plasma in Osteoarthritis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About platelet rich plasma

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing platelet rich plasma in Osteoarthritis, or all of them as a file.
02

Study summary

Clinical study to evaluate the effect of platelet rich plasma (PRP), a derivative of a patient's whole blood, on short-term patient outcomes following total knee replacement (TKR).

Read the detailed description

The purpose of this clinical study is to evaluate the effect of platelet rich plasma (PRP), a derivative of a patient's whole blood, on short-term patient outcomes following total knee replacement (TKR). The hypothesis is that change in short-term hemoglobin (Hgb) levels is less dramatic in patients who undergo TKR with the addition of PRP when compared to patients who undergo TKR without PRP.

03

Conditions studied

  • Osteoarthritis
  • Inflammatory Arthritis

Keywords

  • Total knee replacement
  • Platelet Rich Plasma
  • PRP
  • Biologic
  • Randomized
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is a male or female who is undergoing primary unilateral surgery or the first surgery of a staged bilateral total knee replacement where the second stage will be at least 6 weeks later PRP in Total Knee.
  2. Patient agrees to be blinded to their treatment group assignment.
  3. Patient is willing and able to return for follow-up over at least a six (6) week post-operative period although longer follow-up is desired
  4. Patient agrees to participate by signing an IRB approved Form

Exclusion criteria

Exclusion Criteria:

  1. Patient will have a staged bilateral total knee replacement with the second stage to be performed less than 6 weeks after the first stage surgery
  2. Patient has had previous surgery on the operative knee that will necessitate the removal of existing hardware (e.g. previous osteotomy)
  3. Patient has a known adverse reaction or sensitivity to bovine (cow) thrombin (used as part of the rich plasma system) or other bovine-derived products
  4. Patient has \< 12.0 (males), \< 11.0 (females)
  5. Patient anxiety disorder
  6. Patient is on therapeutic anticoagulation medication and has an > 1.3
  7. Patient has a severe bleeding disorder
  8. Patient has a known addiction to drugs or alcohol, including, but not limited to: chronic daily use of narcotic medications for more than 90 days prior to surgery
  9. Patient is pregnant
  10. Patient is a prisoner
  11. Patient is involved in a personal litigation (e.g. Worker's Compensation) that relates to their knee surgery
  12. Patient is actively participating in an medical device, drug, or biologic clinical trial (active defined as having treatment within the last 30 days)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    1 (PRP)

    Total knee replacement with PRP

    Biological: Platelet Rich Plasma

  • No intervention
    2 (non-PRP)

    Total knee replacement without PRP

Interventions

  • Addition of PRP to total knee replacement procedure

    Also known as: Accelerate PRP

06

What researchers measure

Primary outcomes

  1. Hemoglobin level

    Hemoglobin level analysis

    Time frame: Change in hemoglobin (Hgb) level (preop compared to postop day 2)

07

Study locations

2 sites
  • Center for Joint Replacement, St. Mary's Regional Medical Center
    Lewiston, Maine 04240, United States
  • Peninsula Orthopedic Associates
    Salisbury, Maryland 21804, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Jun 2011 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2009
First posted
Jan 21, 2009
Start
Dec 2008
Primary completionActual
Jun 2011
CompletionActual
Feb 2013
Last update
Sep 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00826098
Lead sponsor
Exactech
Responsible party
Sponsor
First posted
Jan 21, 2009
Start date
Dec 2008
Primary completion
Jun 2011
Completion
Feb 2013
Last update
Sep 1, 2022

Study contacts

Wayne Moody, MD
principal investigator · Central Maine Orthopaedics, PA
Pasquale Petrera, MD
principal investigator · Peninsula Orthopedic Associates

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Platelet rich plasma

Start the discussion